急性呼吸窘迫综合征后急性肾损伤的时间关系与临床结局:系统评价与Meta分析
该系统评价与Meta分析检索Ovid MEDLINE(R)、Ovid Embase、Ovid Cochrane Central Register of Controlled Trials、Ovid Cochrane Database of Systematic Reviews、Ovid PsycINFO、Scopus和Web of Science至2023年4月,纳入报告ARDS后发生AKI的随机对照试验及前瞻性或回顾性队列研究。共筛查3646项研究,最终纳入17项研究、9359例ARDS患者;3287例(40%)在ARDS诊断后发生AKI,ARDS诊断后至少48小时AKI发生率为20%(95%CI 0.18-0.21%)。发生AKI的ARDS患者住院(或30天)死亡汇总RR为1.93(95%CI 1.71-2.18),多因素分析汇总OR为3.69(95%CI 2.24-6.09);两项比较迟发与早发AKI的研究显示迟发AKI患者死亡率更高,RR为1.46(95%CI 1.19-1.8)。大多数结局的证据确定性为低至极低,作者认为需谨慎解读并需进一步研究。
要点
- ARDS诊断后AKI总体发生率为40%(3287/9359例),ARDS诊断后至少48小时AKI发生率为20%(95%CI 0.18-0.21%)。
- 发生AKI的ARDS患者住院(或30天)死亡汇总RR为1.93(95%CI 1.71-2.18)。
- 多因素分析显示ARDS后发生AKI是死亡的独立危险因素,汇总OR为3.69(95%CI 2.24-6.09)。
- 两项研究比较迟发与早发AKI,迟发AKI患者死亡率更高,RR为1.46(95%CI 1.19-1.8)。
- 大多数结局的证据确定性为低至极低,作者认为需谨慎解读。
适用人群与场景
- 纳入随机对照试验及前瞻性或回顾性队列研究,研究对象为ARDS患者,报告ARDS后发生AKI。
- 共纳入17项研究、9359例ARDS患者。
研究设计与关键结果
- 研究类型:系统评价与Meta分析;共筛查3646项研究,纳入17项研究、9359例ARDS患者。
- AKI发生:3287例(40%)在ARDS诊断后发生AKI;ARDS诊断后至少48小时AKI发生率为20%(95%CI 0.18-0.21%)。
- 住院(或30天)死亡:发生AKI的ARDS患者汇总RR为1.93(95%CI 1.71-2.18)。
- 多因素分析:ARDS后发生AKI为死亡的独立危险因素,汇总OR为3.69(95%CI 2.24-6.09)。
- 迟发与早发AKI比较:两项研究显示迟发AKI患者死亡率更高,RR为1.46(95%CI 1.19-1.8)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入随机对照试验及前瞻性或回顾性队列研究。
- 大多数结局的证据确定性为低至极低。
- 局限:大多数结局的证据确定性为低至极低,作者认为需谨慎解读;该系统评价发现显著的知识缺口,需进一步研究以建立对该关系及其临床意义更明确的理解。
对床旁实践的改变
- 作者认为,尽管研究结果突出显示ARDS与后续发生AKI之间存在显著关联,但低至极低的证据确定性要求谨慎解读。
- 作者指出,该系统评价发现显著的知识缺口,需进一步研究以建立对该关系及其临床意义更明确的理解。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Conduct a systematic review and meta-analysis to assess prevalence and timing of acute kidney injury (AKI) development after acute respiratory distress syndrome (ARDS) and its association with mortality.
DATA SOURCES: Ovid MEDLINE(R), Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, Ovid PsycINFO database, Scopus, and Web of Science thought April 2023.
STUDY SELECTION: Titles and abstracts were screened independently and in duplicate to identify eligible studies. Randomized controlled trials and prospective or retrospective cohort studies reporting the development of AKI following ARDS were included.
DATA EXTRACTION: Two reviewers independently extracted data using a pre piloted abstraction form. We used Review Manager 5.4 software (Cochrane Library, Oxford, United Kingdom) and Open Meta software (Brown University, Providence, RI) for statistical analyses.
DATA SYNTHESIS: Among the 3646 studies identified and screened, 17 studies comprising 9359 ARDS patients met the eligibility criteria and were included in the meta-analysis. AKI developed in 3287 patients (40%) after the diagnosis of ARDS. The incidence of AKI at least 48 hours after ARDS diagnosis was 20% (95% CI, 0.18-0.21%). The pooled risk ratio (RR) for the hospital (or 30-d) mortality among ARDS patients who developed AKI was 1.93 (95% CI, 1.71-2.18). AKI development after ARDS was identified as an independent risk factor for mortality in ARDS patients, with a pooled odds ratio from multivariable analysis of 3.69 (95% CI, 2.24-6.09). Furthermore, two studies comparing mortality between patients with late vs. early AKI initiation after ARDS revealed higher mortality in late AKI patients with RR of 1.46 (95% CI, 1.19-1.8). However, the certainty of evidence for most outcomes was low to very low.
CONCLUSIONS: While our findings highlight a significant association between ARDS and subsequent development of AKI, the low to very low certainty of evidence underscores the need for cautious interpretation. This systematic review identified a significant knowledge gap, necessitating further research to establish a more definitive understanding of this relationship and its clinical implications.
参考来源
- Charkviani M, Truong HH, Nikravangolsefid N, et al. Temporal Relationship and Clinical Outcomes of Acute Kidney Injury Following Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis. Crit Care Explor. 2024. PMID: 38352941. doi:10.1097/CCE.0000000000001054
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。